To include your compound in the COVID-19 Resource Center, submit it here.

Amgen ASCO lineup includes denosumab, AMG 386 data

Amgen Inc. (NASDAQ:AMGN) announced the availability of abstracts slated for presentation at the upcoming American Society of Clinical Oncology meeting, including ones for Phase II

Read the full 255 word article

Trial Subscription

Get a two-week free trial subscription to BioCentury

SIGN UP

Article Purchase

This article may not be distributed to non-subscribers
More Info >PURCHASE